Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (12984)	1/3/1998 3:23:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 32384

Great site, Henry. Thought it was worthwhile copying the market potential for the thread. Actinic keratosis are precancerous lesions caused by exposure to the sun and are more common in light skinned people. 1.5MM is a significan target population. Also noted that the psoriasis indication was for severe psoriasis which is a much smaller market than the entire psoriasis market but still good sized. I was surprised at the number of indications but of course they will not all prove viable. Potential Markets TargretinTM (LGD1069): NEW PATIENTS PER YEAR (U.S.) Actinic keratoses: 1.5 million Diabetes (Type II): 15 million (total patients) Head and neck cancer: 39,750 Kaposi's sarcoma: 22,200 Lung cancer: 169,900 Ovarian cancer: 26,600 Prostate cancer: 244,000 Skin lymphoma: 6,000 PanretinTM* (ALRT1057): NEW PATIENTS PER YEAR (U.S.) APL: 2,500 Breast cancer: 182,000 Kaposi's sarcoma: 22,200 Ovarian cancer: 26,600 Prostate cancer: 244,000 Severe psoraisis: 157,000